Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Emmes logo — The Industry’s First Native Digital and AI Specialty CRO

Emmes

The Industry’s First Native Digital and AI Specialty CRO

Founded 1977 United States Rockville, United States 1294 employees Private Equity Biopharma, Biotechnology +1

General Information

Company Name Emmes
Founded Year 1977
Location United States Rockville, United States
Founders / Decision Makers
Team member
Employees 1294
Industries Biopharma, Biotechnology, Health Care
Funding Stage Private Equity
Social

BounceWatch is an independent company data service, not affiliated with Emmes. To contact Emmes, visit emmes.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Emmes

Emmes is a leading Contract Research Organization that has been at the forefront of clinical research for over 40 years. Headquartered in the United States and with offices in Europe, Canada, and India, Emmes is dedicated to conducting clinical research with scientific rigor and compliance with global regulatory standards. The company specializes in a wide range of therapeutic areas, with a focus on Vaccines and Infectious Diseases, Ophthalmology, Immunology, and Neuroscience. Emmes has an impressive track record, with involvement in over 2,000 clinical trials and contributions to over 2,500 publications that advance the understanding of medicine and public health globally. In March 2019, Emmes secured a Private Equity Round investment with Behrman Capital and Delancey Street Partners as the investors. This investment reflects the confidence of leading financial institutions in Emmes' capabilities and its potential for future growth and innovation. Emmes stands out as the industry’s first native digital and AI Specialty CRO, committed to leveraging innovative technologies and data management platforms to provide a multi-faceted approach to meet the evolving research objectives of its clients. With a focus on diversity, inclusivity, integrity, and operational excellence, Emmes is well-positioned to continue supporting global public health and biopharmaceutical innovation.

Taxonomy: Contract Research Organization, Clinical Research, Public Health, Biopharmaceutical Innovation, Vaccines, Infectious Diseases, Ophthalmology, Immunology, Neuroscience, Pandemic Research, Cell and Gene Therapy, Global Clinical Research, Biostatistics, Rockville

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round Undisclosed 2
Behrman Capital Delancey Street Partners
Behrman Capital, Delancey Street Partners
04 Mar 2019

Emmes Alternatives & Competitors

View All Alternatives
Emmes vs
hVIVO
hVIVO United Kingdom

A rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human ch...

Series B
248 employees
Biotechnology, Health Care
Emmes vs
EMERGEX VACCINES LTD
EMERGEX VACCINES LTD United Kingdom

A UK biotechnology company developing T cell-priming immune set-point candidates against infectious...

Grant
1 employees
Biopharma, Biotechnology
Emmes vs
Miltenyi Biotec
Miltenyi Biotec Germany

Empowering discovery. Advancing therapy.

3348 employees
Biotechnology, Health Care
View all alternatives

FAQ About Emmes

The Industry’s First Native Digital and AI Specialty CRO
Emmes was founded in 1977.
Emmes is headquartered in Rockville, United States.
Emmes operates in Biopharma, Biotechnology and Health Care. Its work centres on Contract Research Organization, Clinical Research, Public Health and Biopharmaceutical Innovation.
Emmes has approximately 1294 employees.
Emmes has completed 1 funding round. The latest funding stage is Private Equity.
Top alternatives and competitors to Emmes include hVIVO, EMERGEX VACCINES LTD, Miltenyi Biotec, Tmunity Therapeutics, Osivax. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Emmes and hVIVO are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Emmes, https://bouncewatch.com/company/emmes, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes